IRONWOOD PHARMACEUTICALS, INC. Contract Liability (Deferred Revenue)
IRONWOOD PHARMACEUTICALS, INC. (IRWD) had Contract Liability (Deferred Revenue) of $1.25 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-06
- 2026-06-30: Contract with Customer, Liability, Current $1.25M.
- 2026-03-31: Contract with Customer, Liability, Current $1.47M.
- 2025-12-31: Contract with Customer, Liability, Current $1.11M.
- 2025-09-30: Contract with Customer, Liability, Current $1.05M.
| Period end | Contract with Customer, Liability, Current | Contract with Customer, Liability, Current as first filed |
|---|---|---|
| 2026-06-30 | $1.25M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $1.47M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $1.11M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $1.05M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $978.00K 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $1.80M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $2.03M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $1.90M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $2.10M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $1.70M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $2.62M 10-K · filed 2025-03-31 | $2.60M 10-K · filed 2024-02-16 |
| 2023-09-30 | $2.60M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $1.50M 10-Q · filed 2023-08-09 | |
| 2020-09-30 | $875.00K 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $875.00K 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $875.00K 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $875.00K 10-K · filed 2021-02-17 | |
| 2019-09-30 | $1.28M 10-Q · filed 2019-10-31 | |
| 2018-09-30 | $13.52M 10-Q · filed 2018-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |